Search Results for: CIRM

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future

VC-01-post-implant-final1-e1503703572933, viacyte

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on […]

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »

Recommended reading for innovative, evidence-based medicine

evidence-based-medicine

One of my goals is promoting evidence-based medicine and science-based medicine that is in the best interest of the community including patients. Below is a list of recommended reading for you including mostly blogs, but also other resources that should be on your regular must-read list. Some are stem cell-focused, while most are broader. California

Recommended reading for innovative, evidence-based medicine Read More »

WAFSF stem cell vision talks: Hinton, Tsukamoto, Klassen, Takahashi

Henry-Klassen

Recently I was at the World Alliance Forum in San Francisco (WAFSF), a great meeting on stem cells and regenerative medicine. WAFSF had some excellent talks and I saw one session on the use of stem cells to treat vision impairment that was particularly striking. World Alliance Forum in San Francisco (WAFSF) This session’s all-star lineup included Drs. David

WAFSF stem cell vision talks: Hinton, Tsukamoto, Klassen, Takahashi Read More »

Super Cells exhibit and why we bother with public outreach

Super-Cells

What are super cells? Guest post by Lisa Willemse Last month, on this blog, Paul wrote an article about loopholes in the clinicaltrials.gov database that allows for-profit companies to advertise their “therapies” under the guise of a registered clinical trial. This is a real concern for our community, especially those among us who have recommended

Super Cells exhibit and why we bother with public outreach Read More »